pyrazines has been researched along with Protein Aggregation, Pathological in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, H; Deng, X; Du, H; Huang, H; Kuang, X; Ling, X; Long, C; Shen, H; Shi, K; Tang, H; Wang, L; Wang, R; Xing, Y; Yan, J; Zhang, H; Zhu, X; Zou, Y | 1 |
| Bonhaus, D; Khan, A; Koike, MA; Masliah, E; Price, DL; Rockenstein, E; Wrasidlo, W | 1 |
| Bender, S; Bonaud, A; Bridoux, F; Cogné, M; Delpy, L; Druilhe, A; Javaugue, V; Lacombe, C; Oblet, C; Quellard, N; Sirac, C; Srour, N; Touchard, G | 1 |
3 other study(ies) available for pyrazines and Protein Aggregation, Pathological
| Article | Year |
|---|---|
2,3,5,6-Tetramethylpyrazine protects retinal photoreceptors against endoplasmic reticulum stress by modulating ATF4-mediated inhibition of PRP aggregation.
Topics: Activating Transcription Factor 4; Animals; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Electroretinography; Endoplasmic Reticulum Stress; Eye Proteins; Fasting; Female; Glucose; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Prion Proteins; Protein Aggregates; Protein Aggregation, Pathological; Pyrazines; Retina; Retinal Cone Photoreceptor Cells; Retinal Degeneration; Single-Blind Method; Solubility; Specific Pathogen-Free Organisms; Transcription, Genetic | 2021 |
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cerebral Cortex; Disease Models, Animal; Gene Expression Regulation; Humans; Inflammation; Lewy Body Disease; Mice; Mice, Transgenic; Multiple System Atrophy; Neurons; Parkinson Disease; Piperidines; Protein Aggregation, Pathological; Protein Folding; Pyrazines; Pyrimidines; Retina | 2018 |
A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression; Genetic Loci; Heavy Chain Disease; Humans; Immunoglobulin Heavy Chains; Kidney Diseases; Kidney Glomerulus; Mice; Mice, Transgenic; Molecular Sequence Data; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Aggregation, Pathological; Protein Structure, Tertiary; Pyrazines; Sequence Deletion; Unfolded Protein Response | 2015 |